Get the Stockscreener App
19.57
11.51%
2.02
After Hours:
19.62
0.05
+0.26%
Metsera Inc stock is traded at $19.57, with a volume of 1.30M.
It is up +11.51% in the last 24 hours and down -31.04% over the past month.
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$17.55
Open:
$17.51
24h Volume:
1.30M
Relative Volume:
1.98
Market Cap:
$1.91B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+49.62%
1M Performance:
-31.04%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.34
$19.64
1-Week Range:
$12.82
$20.46
52-Week Range:
$12.30
$32.81
Metsera Inc Stock (MTSR) Company Profile
Name
Metsera Inc
Sector
Industry
Phone
(212) 784-6595
Address
3 WORLD TRADE CENTER, NEW YORK
Compare MTSR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
19.57 | 1.91B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-25 | Initiated | BofA Securities | Buy |
| Feb-25-25 | Initiated | Evercore ISI | Outperform |
| Feb-25-25 | Initiated | Guggenheim | Buy |
Metsera Inc Stock (MTSR) Latest News
Lilly stock up rallying Structure and Metsera (GPCR:NASDAQ) - Seeking Alpha
Viking, Structure, Metsera on a tear as Pfizer drops obesity pill - MSN
Viking stock on a tear after Pfizer setback (VKTX:NASDAQ) - Seeking Alpha
Metsera plunges 44% after InvestingPro’s overvaluation warning By Investing.com - Investing.com South Africa
Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025 - Endpoints News
Metsera sees cash runway into 2027 - TipRanks
Metsera reports Q4 EPS ($3.52) vs. (94c) last year - TipRanks
Decoding Metsera Inc (MTSR): A Strategic SWOT Insight - GuruFocus
Are Metsera Inc’shares a good deal? - US Post News
Metsera's Q4 Net Loss Widens, Operating Expenses Rise; Shares Higher - marketscreener.com
Metsera Reports Fourth Quarter And Full Year 2024 Financial Results And Continued Portfolio Progress - Marketscreener.com
Form 10-K Metsera, Inc. For: Dec 31 - StreetInsider
Earnings Flash (MTSR) Metsera Posts Q4 Total Operating Expenses $64.5M - Marketscreener.com
Earnings Flash (MTSR) Metsera Posts Q4 Net Loss of $3.52 a Share - MarketScreener
Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress - The Manila Times
Metsera Inc (NASDAQ: MTSR) Stock Is Down -21.4% From Its Low: The Uptrend Is Still On - Stocks Register
Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - insights.citeline.com
IHS Holding Posts Upbeat Earnings, Joins Tencent Music Entertainment, Elbit Systems And Other Big Stocks Moving Higher On TuesdayDiginex (NASDAQ:DGNX), China Liberal Education (NASDAQ:CLEU) - Benzinga
Metsera, Inc. (MTSR): Among Top Insider Purchases Last Month - Insider Monkey
Top 10 Insider Purchases Last Month - Insider Monkey
Metsera, Inc. awards full bonuses to executive officers By Investing.com - Investing.com Australia
Metsera, Inc. awards full bonuses to executive officers - Investing.com India
Metsera, Inc. Approves 2024 Executive Cash Bonuses - TipRanks
Is Metsera, Inc. (MTSR) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
Why MicroStrategy Incorporated (MSTR) Soared on Tuesday - MSN
Metsera, Inc.’s Quiet Period To Expire on March 12th (NASDAQ:MTSR) - Defense World
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing - NewsBreak
Why Did Metsera Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has Happened Since Its Listing - Benzinga
Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
10 Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
AbbVie Buys Into Obesity With Gubra Deal, While Novo Partners With Gensaic - insights.citeline.com
10 Best Weight Loss Drug Stocks to Buy According to Analysts - Insider Monkey
CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases - ACCESS Newswire
Metsera to Present at TD Cowen's 45th Annual Health Care Conference - The Manila Times
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference - The Bakersfield Californian
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation - Seeking Alpha
Metsera (NASDAQ:MTSR) Now Covered by Bank of America - Defense World
Metsera (NASDAQ:MTSR) Now Covered by Analysts at Evercore ISI - Defense World
Metsera started by Guggenheim at buy on obesity drug opportunity - MSN
Wall Street bullish on Metsera following January IPO on obesity drug pipeline - Investing.com Canada
Metsera started at buy at Guggenheim on obesity treatment potential - MSN
Why this newly public biotech could become a force in obesity treatments - MarketWatch
90% upside? This weight-loss drug play is worth a look - Invezz
This weight-loss drug stock could deliver a 90% return in 2025 - TradingView
Cantor Fitzgerald initiates Metsera with overweight rating - Investing.com India
Metsera Inc Stock (MTSR) Financials Data
There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):